Objective Although the majority of cases of cystic fibrosis (CF) are now diagnosed through newborn screening, there is still a need to standardize the diagnostic criteria for those diagnosed outside of the neonatal period. This is because newborn screening started relatively recently, it is not performed everywhere, and even for individuals who were screened, there is the possibility of a false negative. To limit irreversible organ pathology, a timely diagnosis of CF and institution of CF therapies can greatly benefit these patients.
Results CF diagnosis in individuals outside of newborn screening relies on the clinical evidence and on evidence of CF transmembrane conductance regulator (CFTR) dysfunction. Clinical evidence can include typical organ pathologies seen in CF such as bronchiectasis or pancreatic insufficiency but often represent a broad range of severity including mild cases. CFTR dysfunction can be demonstrated using sweat chloride testing, CFTR molecular genetic analysis, or CFTR physiologic tests. On the basis of the large number of patients with bona fide CF currently followed in registries with sweat chloride levels between 30 and 40 mmol/L, the threshold considered "intermediate" was lowered from 40 mmol/L in the prior diagnostic guidelines to 30 mmol/L. The CF diagnosis was also discussed in the context of CFTR-related disorders in which CFTR dysfunction may be present, but the individual does not meet criteria for CF.
Conclusions CF diagnosis remains a rare but important condition that can be diagnosed when characteristic clinical features are seen in an individual with demonstrated CFTR dysfunction. (J Pediatr 2017;181S:S52-7).
S ince the identification of cystic fibrosis (CF) as a pathologic entity in 1938, 1 diagnosis has been based on the appearance of signs and symptoms of the disease. For many decades, diagnosis occurred in infancy or early childhood, although by the 1960s, the disease was occasionally being identified in adults, [2] [3] [4] who were usually pancreatic-sufficient. The identification of the gene for the CF transmembrane conductance regulator (CFTR) in 1989 [5] [6] [7] and subsequent discovery of mutations that can alter quantity and/or function of the protein to varying degrees, 8 as well as the recognition of modifier genes, 9 have led to demonstration of a wider spectrum of CF in individuals of all ages and ethnicities. 10 It is now clear that in individuals with residual function CFTR mutations, clinical manifestation of CF may develop later in life. 11 Furthermore, although the advent of widespread newborn screening (NBS) has dramatically changed the diagnosis for many infants born in the last decade or so, more than one-third of all US diagnoses in 2014 were not a result of NBS. 12 Criteria to establish a diagnosis of CF outside of NBS are needed because CF NBS is neither universal nor foolproof; false negatives can and do occur. 12, 13 Thus, although physicians today may have less clinical suspicion as a result of CF NBS, a diagnosis of CF or related entities must remain a consideration in anyone who displays signs and symptoms of the disease, regardless of age, race, or whether they may have undergone NBS.
Diagnosis of the Nonscreened Individual
The process for diagnosis of CF in individuals that present with clinical symptoms rather than a positive newborn screen does not differ greatly from that recommended by earlier diagnosis consensus criteria 13 (flow chart representing the diagnostic process recommended for all populations by the 2015 CF diagnosis consensus committee 14 ). There is growing recognition that CF can present at any age, and in any race or ethnicity. In making the diagnosis, an appropriate clinical presentation needs to be linked with evidence of CFTR dysfunction. Since earlier consensus statements, several advances have evolved our experience with both the clinical presentation (as we have recognized a broader spectrum of CF and CFTR-related disorders) and with our understanding of the molecular and cellular pathophysiology of CFTR dysfunction (increased genetic annotation and improved physiologic testing of CFTR). This article will place those advances in the context of CF diagnosis in the era of expanded CF therapeutics.
As part of the US CF Foundation Diagnosis Consensus Conference, convened in Phoenix, Arizona, in October 2015, the criteria for CF diagnosis were reviewed. This review included recent advances in changes to diagnosis for screened individuals, as well as for nonscreened. A summary of the conference was organized according to consensus statements and voted on by participants in the conference, as well as opened to public comment. The summary review and other articles can be viewed as part of this Supplement. [14] [15] [16] [17] [18] The consensus statements pertaining specifically to nonscreened individuals are listed in Table I .
Steps to Establish CF Diagnosis
When the diagnosis of CF is being considered outside of the NBS context, the presenting signs and symptoms (Table II) play an important role in defining likelihood of CF. An individual with multiple typical-organ system manifestations of CF (bronchiectasis, sinus polyps, and pancreatic insufficiency) has a higher probability of having CFTR dysfunction as the explanation of their phenotype compared with someone with only atypical manifestations of CF (eg, isolated symptoms such as chronic cough or sputum production without bronchiectasis, recurrent pancreatitis) that may have alternative explanations. Therefore, diagnosis of CF can be heavily influenced by the pretest probability or how well the phenotype is consistent with CF as we understand it now.
Coincident with the consideration of presenting signs and symptoms for CF, the clinician must also compare these with ABPA, allergic bronchopulmonary aspergillosis; GI, gastrointestinal. *Many of the uncommon presentation clinical features are not uncommon in patients with CF (ABPA, nontuberculous mycobacterial infection, abnormal motility, clubbing, vitamin deficiencies), however, they are uncommon as isolated presenting complaint that ultimately is due to CF. Atypical mycobacterial infection has more commonly led to a diagnosis of CF in adults.
alternative diagnoses. Comprehensive lists of alternative diagnoses are beyond the scope of this article and will differ according to the specific clinical presentation and the age of the patient. For example, an individual presenting with bronchiectasis will have a different differential diagnosis (immune deficiency, prior infection, ciliary dyskinesia, etc) than an individual with primarily pancreatitis (alcohol toxicity, gallstones, hypertriglyceridemia, etc). To evaluate other potential etiologies, the clinician may rely on tests that better characterize the presenting signs and symptoms, or that test for a specific alternative diagnosis. Those tests may include:
(1) pulmonary function tests; (2) high-resolution chest computed tomography (CT); (3) respiratory tract cultures from sputum or bronchoalveolar lavage; (4) fecal fat quantification or elastase antibodies; (5) pancreatic imaging; (6) fatsoluble vitamin levels; (7) genital evaluation in males to evaluate for the bilateral absence of vas deferens; and (8) exclusionary testing for ciliary dyskinesia, immunodeficiencies, recurrent pancreatitis, celiac disease, and inflammatory bowel disease.
Informed with a pretest probability that compares the likelihood of CF vs an alternative explanation, the clinician will interpret genetic analysis and tests for CFTR function (sweat chloride testing, nasal potential difference [NPD], or intestinal current measurement [ICM]) to support or refute a CF diagnosis. Often, when a patient is referred for CF evaluation, some of these tests may have already been performed. A clinician would best interpret these tests in the context of a reasoned pretest probability. The tests of CFTR function may point in a clear single direction (eg, if the sweat chloride is >60 mmol/L and 2 CF-causing CFTR mutations are found, vs an alternative scenario of only 1 mutation found, and the sweat chloride and NPD are normal). Challenges arise if those CFTR tests do not provide a definitive answer. Examples of this could include an intermediate sweat chloride level (30-59 mmol/ L), the detection of at least 1 CFTR mutation of varying or uncertain clinical consequence, or NPD/ICM that cannot be interpreted as positive or negative. In these circumstances, the clinician may refer to their pretest probability. It is important to note that diagnostic challenges should not delay potentially beneficial treatments.
Change in Sweat Chloride Range Definitions
A major change that resulted from the 2015 Diagnosis Consensus Conference was the adoption of a lower sweat chloride level as the upper limit of normal. The 2008 diagnosis consensus 19 recommended the use of ≥60 mmol/L chloride in the sweat as diagnostic of CF, with levels from 30 to 59 mmol/L as intermediate sweat chloride values in infants under 6 months of age, or 40-59 mmol/L in individuals over 6 months of age. After reviewing evidence accumulated in the interim (eg, Augarten et al, 25 Highsmith et al, 26 and Collaco et al The basis for a sweat chloride level of <60 mmol/L in individuals who are diagnosed with CF because of a preponderance of clinical symptoms can be attributed in large part to the occurrence of CFTR mutations that do not result in a total loss of chloride channel activity. The Clinical and Functional Translation of CFTR (CFTR2) was established to determine the clinical and functional impact of various CFTR mutations. 8 Phenotype and genotype information are collected from patient registries, and disease-liability of each CFTR mutation is evaluated through a combination of in vivo (sweat chloride) and in vitro data (functional activity identified in cell-based systems). The CFTR mutations are sorted into 4 categories: (1) CF-causing (defined as resulting in CF when 2 copies are present in an individual); (2) a mutation of varying clinical consequence (defined as a mutation that, in combination with a CF-causing mutation or another mutation of varying clinical consequence may result in CF); (3) a mutation of unknown clinical consequence (defined as one that has not been evaluated by CFTR2); and (4) a mutation that is non-CF-causing (defined as not causing CF when present). Thus, consulting the CFTR2 database to determine the disease liability categories represented by an individual genotype may offer better insight into the questionable cases. Table III provides 
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to have CF, could be reconsidered as having a possible diagnosis of CF under the current guidelines. Of course, in subjects with a sweat chloride from 30 to 40 mmol/L, the physician must still rely on other criteria to establish or exclude a CF diagnosis. In general, this highlights that regardless of the test cut-offs used, CF diagnosis in nonscreened individuals needs to appropriately consider all diagnostic test results in the context of the clinical scenario.
Alternative or Unresolved Diagnoses

CFTR-Related Disorders
An important advance since the publication of the last US CF Foundation diagnostic consensus criteria is a better definition of CFTR-related disorders. 28 This is simply defined as a clinical entity associated with CFTR dysfunction, that does not fulfill diagnostic criteria for CF. 28 It has been particularly ascribed to clinical entities such as congenital bilateral absence of the vas deferens, recurrent pancreatitis, and disseminated bronchiectasis. This traditionally has been diagnosed in adults. An argument can be made that an individual with bronchiectasis as a manifestation of CFTR-related disorder should be labeled as CF. However, because there are many causes of bronchiectasis (including various immunodeficiencies, primary ciliary dyskinesia, and sequellae of pneumonia), the identification of a single CF-causing mutation, as exists in the parents of an individual with CF, is not uncommon. The clinician must be cautioned not to conclude too readily that a symptom is the result of CFTR dysfunction. Rather, it would be prudent simply to treat the individual following CF guidelines while the diagnosis is being resolved.
It also has been recognized that variance in the CFTR gene may play a contributing role in bronchiectasis and other organ pathologies. For example, among individuals with bronchiectasis, there is a higher than general-population incidence of CFTR mutations, [29] [30] [31] [32] [33] including mutations with only minor effects on CFTR function that are not classified as CF-causing, and that are seen commonly in the population. Similar genetic analysis shows CFTR mutations in patients with congenital bilateral absence of the vas deferens, 34-37 chronic sinusitis, 38 and pancreatitis. 39, 40 At this point, the distinction between CFTR-related disorders and conditions in which CFTR mutation or mutations are contributing to complex traits is blurred. Individuals that are carriers (only 1 mutated CFTR allele) may present with a manifestation of reduced CFTR function (for example, chronic sinusitis). 38 The clinical entity of CFTR-related disorder is an important recognition that CFTR variation may impact a much wider segment of the population, beyond those with the lifeshortening Mendelian disease. However, in light of newly approved and future CFTR modulating therapies that can result in significant improvements in quality and length of life, it will be worth identifying the disease liability of an individual genotype, to determine whether the CFTR mutations may be the primary (or modifiable) cause of the phenotype. This will need to be studied with epidemiologic comparison of the genome of individuals with and without traits potentially related to CFTR dysfunction. 41 
Cases in Which a CF Diagnosis Cannot be Resolved
It would be useful to place CFTR-related disorders and complex traits in which CFTR may be playing a role, into an algorithm for CF diagnosis. In cases in which there is a clinical suspicion for CF, but sweat chloride testing, CFTR mutation analysis, and physiologic testing cannot rule in or rule out CF, the clinician is left with a decision. Ultimately in these cases, if the physician believes CF therapies or CF follow-up would benefit the patient, that should outweigh equivocal, nondiagnostic, test results.
The goal must be to achieve optimal treatment, especially of lung disease, rather than to engage in an ongoing debate about the best diagnostic label. The European CF Society Diagnostic Network Working Group has advocated for the use of the term "atypical" CF. 20, 21 Although these cases may not follow the "typical" path of CF, patients who do not display 2 CF-causing mutations or do not have diagnostic sweat chloride test results can still have severe, life-limiting respiratory disease. 42, 43 In fact, there are no CFTR mutations that can be exclusively characterized as "atypical" mutations (although some mutations may trigger more risk than others 44 ). Thus, the diagnosis consensus committee has agreed (not universally) to recommend against the use of the terms atypical or borderline CF. Most, although not all, of the committee has concluded that if a CF clinician feels CF therapies and follow-up would benefit the individual and other potential diagnoses are ruled out, the CF diagnosis is appropriate. This certainly is influenced by the third-party payers in the US that may be more likely to cover expensive care if a CF diagnosis is used. Regardless, in individuals diagnosed with CF as an adult or with milder presentations, appropriate counseling should include that the life expectancy estimates derived from mostly patients with CF diagnosed early in life are less applicable in their situation.
Inconclusive Result after CF NBS
It is important to note that the uncertain diagnostic category that can result from positive newborn screens that do not meet criteria for CF (ie, CF-related metabolic disorder/CF screen positive, inconclusive diagnosis) does not apply to anyone presenting with CF-like symptoms. 14, 18 However, individuals identified in NBS that do not have CF frequently have mutations that are seen more commonly in individuals with CFTRrelated disorders. 45 Some of these individuals identified in NBS may go on to develop a CFTR-related disorder later in life. Future study of the likelihood of developing these conditions is needed, but this will require long-term follow-up. In the meantime, counseling parents of CFTR-related metabolic syndrome/CF screen positive, inconclusive diagnosis infants about this possibility is an important component of NBS programs. Clinicians considering CF in a nonscreened setting should ask questions about NBS history. 
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Special Considerations Regarding Adult Diagnosis
In the period from 1995 to 2005, there were 9766 new CF diagnoses, of which 811 (8.3%) were in adults, with a mean age of 34 years at the time of diagnosis. 42 Some examples of adult diagnoses can be found in the case studies shown in the Appendix (available at www.jpeds.com). Most adults (70.6%) present with commonly described respiratory symptoms, such as Pseudomonas lung infections and reduced lung function. Despite the delayed appearance of symptoms, the causes of death do not differ significantly from those experienced by patients diagnosed in childhood, with the vast majority of both caused by respiratory failure (87% following childhood diagnosis, 85% following adult diagnosis). 43 The importance of recognizing these later presentations of CF is that there is tremendous opportunity to intervene in progressive lung disease. Unlike asymptomatic babies who are diagnosed through NBS, these patients (or their parents) are actively seeking a diagnosis to facilitate treatment. A CF diagnosis often comes as a relief in these individuals. 46 Beyond this, establishing the diagnosis is critical to help these individuals access the specialized care, genetic counseling, and drugs they need. Without a CF diagnosis, there may be challenges getting insurance to pay for necessary therapies. The "diagnostic odyssey" is prolonged, and further unnecessary testing and uncertainty will ensue.
Discussion
Given the multitude of different organ systems that can be involved in CF, establishing a diagnosis in an individual presenting with symptoms does not lend itself well to protocols or algorithms, such as those used in newborn screening. The central tenant that an individual with a clinical scenario (symptoms, signs, and/or family history) and evidence of CFTR dysfunction (sweat test, CFTR genotype, CFTR physiologic testing with NPD or ICM) has CF is true regardless of the situation, but in nonscreened individuals, the diagnosis demands different clinician recognition and judgment. NBS has been a tremendous improvement in CF detection, but it will never eliminate the need to consider CF as a clinical diagnosis in individuals who were not screened or who were not identified. CF was recognized as a clinical entity before the genetic cause was determined. However, as the range of genetic variations identified in CFTR has expanded, so too must our understanding of the clinical entity. The clinician must now look beyond traditional presentations to consider milder cases of CF and situations in which CFTR dysfunction is playing a role in lung, gastrointestinal, or reproductive tract disorders. It is the goal of the CF community to refine these diagnostic criteria in a way that gets CF care and therapeutic advances to those that would benefit the most from them, but also to inform the clinician to help all those in whom the disease should be considered. ■ Author Disclosures P.S. receives grant funding from the CF Foundation. T.W. is an employee of the CF Foundation. P.F. receives honoraria from the CF Foundation as National Facilitator for NBS Quality Improvement. K.dB receives funding from Vertex Pharmaceuticals, Ablynx, Aptalis, Galapagos, Gilead, Pharmaxis, and PTC Therapeutics. The other authors declare no conflicts of interest.
A.
She is only a CF carrier because full CFTR gene sequencing did not demonstrate 2 CF-causing mutations B.
She does not meet diagnostic criteria for CF because her sweat chloride is <60 mmol/L C.
The absence of detection of 2 CF-causing mutations does not exclude a diagnosis of CF D.
Both A and B
C -correct
This case demonstrates the role of clinical judgment in establishing the CF diagnosis in certain individuals. The patient presents with a disease phenotype consistent with CF, combined with a strong family history in a first-degree relative. With currently available analysis, only a single CFTR mutation can be identified, but her sweat chloride test is grossly abnormal, although below the standard diagnostic cut-off. As our understanding of CFTR structure, function and regulation continues to grow, it is likely that at some point a second gene defect will be discovered in this individual, but in the meantime she should be given the diagnosis of CF and provided access to CF center care.
Which of the following statements is correct?
A.
A sweat chloride of 54 mmol/L is typical of a carrier of a single copy of F508del B.
NPD testing is necessary to establish a CF diagnosis C.
She can be assigned the diagnosis of CF based on clinical presentation, family history and demonstrated CFTR dysfunction D.
She does not have CF and neither did her sister C -correct In general, CF carriers will not have an abnormal sweat chloride. NPD testing could confirm the degree of CFTR dysfunction assessed by the sweat chloride testing, but it should not delay the institution of CF therapies. The strong family history should not be dismissed unless a more plausible hereditary cause of bronchiectasis can be proven in this case. Her sweat chloride of 54 mmol/L is entirely consistent with her clinical presentation at this point in life.
Case Study 3
A 20-year-old woman presents with recurrent hemoptysis and a productive cough since age 11 years. She has had a history of many respiratory infections, and her episodes of bleeding have become more frequent and severe. She has chronic sinusitis and nasal polyps. She has symptoms consistent with typical steatorrhea and is underweight. She has never had pancreatitis. She denies a family history of CF. At presentation, her initial sputum culture demonstrated P aeruginosa and methicillin-sensitive Staphylococcus aureus. A chest CT scan was significant for mild upper lobe bronchiectasis and scattered mucous plugging. Her FEV1 was 70% predicted. Analysis of CFTR function demonstrated a mean sweat chloride value of 33 mmol/L. CFTR genotype revealed the presence of 1 copy c.1521_1523delCTT (legacy: F508del) and 1 copy c.3737C>T (legacy: T1246I).
She was initiated on inhaled tobramycin and standard airway clearance. Subsequent cultures have continued to grow methicillin-sensitive Staphylococcus aureus, and intermittently P aeruginosa, P fluorescens/putida, and Serratia marcescens. She was initiated on pancreatic enzyme replacement, with resolution of steatorrhea. After 2 years of CF center care, her FEV1 has improved to 101%, with marked reduction in hemoptysis and decreased cough. She has gained 3 kg.
Which of the following statements are correct?
A sweat chloride of 33 mmol/L is too low to consider a diagnosis of CF B.
T1246I has not been established as "disease-causing" and therefore this patient is unlikely to have CF C.
The diagnosis of CF can be made on clinical judgment in patients with rare CFTR mutations of unknown significance D.
The benefit to an individual patient from standard CF therapies confirms the diagnosis of CF C -correct This case demonstrates a rare presentation of CF diagnosed early in adulthood.
Her clinical features are typical for CF, including bronchiectasis, infection with usual CF pathogens, chronic sinusitis, and pancreatic insufficiency. Although her sweat chloride is relatively low, the diagnostic criteria developed at the 2015 CF Foundation Consensus Conference acknowledges the potential to develop CF with sweat chlorides ranging from 30 to 59 mmol/L. Even though 2 CFTR mutations were identified, the second is very rare and not wellcharacterized. However, there is no other plausible explanation for her combination of clinical findings combined with evidence of CFTR dysfunction. The diagnosis of CF best fits her clinical presentation at this time, and offers her access to therapies that are likely to extend her life. Her response to therapies is certainly fortunate, but many patients with bronchiectasis without CF may also respond to these treatments. Appropriate care takes priority over establishing a label, but it would be inaccurate to diagnose everyone who responds to CF therapies as having CF.
Which of the following statements is correct?
A. In patients with symptoms consistent with CF and low sweat chloride values or unusual CFTR mutations, it is important to evaluate for causes of their symptoms other than CF B. It is unusual to see pancreatic insufficiency with a low sweat chloride value C. If available, ancillary testing such as NPD could be helpful in this situation D. All of the above D -correct In cases such as this, confidence in the CF diagnosis is increased if other typical causes of bronchiectasis have been ruled out. However, the presence of pancreatic insufficiency in early adulthood is not consistent with other diseases that result in bronchiectasis. In general, patients with sweat chloride values in this range develop bronchiectasis much later in life and are typically pancreatic sufficient. This case demonstrates that in the individual patient, a wide range of disease severity is possible. An NPD test may be of interest in this case but is likely to reflect the findings of the sweat chloride test.
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